Search

Your search keyword '"van der Hulle T"' showing total 196 results
Start Over Author "van der Hulle T"
196 results on '"van der Hulle T"'

6. Sexual quality of life of adolescents and young adult breast cancer survivors

Author

Peeters, N. J.M.C.V., Vlooswijk, C., Bijlsma, R. M., Kaal, S. E.J., Kerst, J. M., Tromp, J. M., Bos, M. E.M.M., van der Hulle, T., Lalisang, R. I., Nuver, J., Kouwenhoven, M. C.M., van der Ploeg, I. M.C., van der Graaf, W. T.A., Husson, O., Peeters, N. J.M.C.V., Vlooswijk, C., Bijlsma, R. M., Kaal, S. E.J., Kerst, J. M., Tromp, J. M., Bos, M. E.M.M., van der Hulle, T., Lalisang, R. I., Nuver, J., Kouwenhoven, M. C.M., van der Ploeg, I. M.C., van der Graaf, W. T.A., and Husson, O.

Abstract

Background: With increasing survival rates of adolescents and young adults (AYAs) with breast cancer, health-related quality of life (HRQoL) becomes more important. An important aspect of HRQoL is sexual QoL. This study examined long-term sexual QoL of AYA breast cancer survivors, compared sexual QoL scores with that of other AYA cancer survivors, and identified factors associated with long-term sexual QoL of AYA breast cancer survivors. Materials and methods: Data of the SURVAYA study were utilized for secondary analyses. Sexual QoL was assessed using the European Organization for Research and Treatment of Cancer Quality of Life cancer survivorship core questionnaire (EORTC QLQ-SURV100). Descriptive statistics were used to describe sexual QoL of AYA cancer survivors. Linear regression models were constructed to examine the effect of cancer type on sexual QoL and to identify factors associated with sexual QoL. Results: Of the 4010 AYA cancer survivors, 944 had breast cancer. Mean sexual QoL scores of AYA breast cancer survivors ranged from 34.5 to 60.0 for functional domains and from 25.2 to 41.5 for symptom-orientated domains. AYA breast cancer survivors reported significantly lower sexual QoL compared to AYA survivors of other cancer types on all domains. Age, time since diagnosis, relationship status, educational level, chemotherapy, hormonal therapy, breast surgery, body image, and coping were associated with sexual QoL of AYA breast cancer survivors. Conclusions: AYA breast cancer survivors experience decreased sexual QoL in the long term (5-20 years) after diagnosis and worse score compared to AYA survivors of other cancer types, indicating a clear need to invest in supportive care interventions for those at risk, to enhance sexual well-being.

Published
2024

7. Sexual quality of life of adolescents and young adult breast cancer survivors

Author

MS Medische Oncologie, Cancer, Peeters, N. J.M.C.V., Vlooswijk, C., Bijlsma, R. M., Kaal, S. E.J., Kerst, J. M., Tromp, J. M., Bos, M. E.M.M., van der Hulle, T., Lalisang, R. I., Nuver, J., Kouwenhoven, M. C.M., van der Ploeg, I. M.C., van der Graaf, W. T.A., Husson, O., MS Medische Oncologie, Cancer, Peeters, N. J.M.C.V., Vlooswijk, C., Bijlsma, R. M., Kaal, S. E.J., Kerst, J. M., Tromp, J. M., Bos, M. E.M.M., van der Hulle, T., Lalisang, R. I., Nuver, J., Kouwenhoven, M. C.M., van der Ploeg, I. M.C., van der Graaf, W. T.A., and Husson, O.

Published
2024

12. Risk of recurrent venous thromboembolism and major hemorrhage in cancer‐associated incidental pulmonary embolism among treated and untreated patients: a pooled analysis of 926 patients

Author

van der Hulle, T., den Exter, P.L., Planquette, B., Meyer, G., Soler, S., Monreal, M., Jiménez, D., Portillo, A.K., O'Connell, C., Liebman, H.A., Shteinberg, M., Adir, Y., Tiseo, M., Bersanelli, M., Abdel‐Razeq, H.N., Mansour, A.H., Donnelly, O.G., Radhakrishna, G., Ramasamy, S., Bozas, G., Maraveyas, A., Shinagare, A.B., Hatabu, H., Nishino, M., Huisman, M.V., and Klok, F.A.

Published
2016
Full Text
View/download PDF

14. Pregnancy-Adapted YEARS Algorithm for Diagnosis of Suspected Pulmonary Embolism

Author

van der Pol, L.M., Tromeur, C., Bistervels, I.M., Ni Ainle, F., van Bemmel, T., Bertoletti, L., Couturaud, F., van Dooren, Y.P.A., Elias, A., Faber, L.M., Hofstee, H.M.A., van der Hulle, T., Kruip, M.J.H.A., Maignan, M., Mairuhu, A.T.A., Middeldorp, S., Nijkeuter, M., Roy, P.M., Sanchez, O., Schmidt, J., Ten Wolde, M., Klok, F.A., and Huisman, M.V.

Published
2019
Full Text
View/download PDF

20. 1630P A multicenter retrospective study on the efficacy of anti-PD-(L)1 in microsatellite unstable (MSI-H) metastatic castrate-resistant prostate cancer (mCRPC)

Author

Van Wilpe, S., Taha, T., Rothmann, E., Altshuler, E., Ledet, E., Bergman, A.M., Tsantoulis, P., Oldenburg, J., Bernard-Tessier, A., Robbrecht, D., Bruijnen, C., Van Der Hulle, T., Antonarakis, E.S., Rothermundt, C.A., Omlin, A.G., Sartor, O., Sena, L., Beltran, H., de Bono, J.S., and Mehra, N.

Published
2024
Full Text
View/download PDF

22. Real-World Metastatic Renal Cell Carcinoma Treatment Patterns and Clinical Outcomes in The Netherlands

Author

van Laar, S. A., Gombert-Handoko, K. B., Groenwold, R. H.H., van der Hulle, T., Visser, L. E., Houtsma, D., Guchelaar, H. J., Zwaveling, J., van Laar, S. A., Gombert-Handoko, K. B., Groenwold, R. H.H., van der Hulle, T., Visser, L. E., Houtsma, D., Guchelaar, H. J., and Zwaveling, J.

Abstract

The number of treatment options for patients with metastatic renal cell carcinoma (mRCC) has significantly grown in the last 15 years. Although randomized controlled trials are fundamental in investigating mRCC treatment efficacy, their external validity can be limited. Therefore, the efficacy of the different treatment options should also be evaluated in clinical practice. We performed a chart review of electronic health records using text mining software to study the current treatment patterns and outcomes. mRCC patients from two large hospitals in the Netherlands, starting treatment between January 2015 and May 2020, were included. Data were collected from electronic health records using a validated text mining tool. Primary endpoints were progression-free survival (PFS) and overall survival (OS). Statistical analyses were performed using the Kaplan–Meier method. Most frequent first-line treatments were pazopanib (n = 70), sunitinib (n = 34), and nivolumab with ipilimumab (n = 28). The overall median PFS values for first-line treatment were 15.7 months (95% confidence interval [95%CI], 8.8–20.7), 16.3 months (95%CI, 9.3–not estimable [NE]) for pazopanib, and 6.9 months (95% CI, 4.4–NE) for sunitinib. The overall median OS values were 33.4 months (95%CI, 28.1–50.9 months), 39.3 months (95%CI, 29.5–NE) for pazopanib, and 28.1 months (95%CI, 7.0–NE) for sunitinib. For nivolumab with ipilimumab, median PFS and median OS were not reached. Of the patients who finished first- and second-line treatments, 64 and 62% received follow-up treatments, respectively. With most patients starting on pazopanib and sunitinib, these real-world treatment outcomes were most likely better than in pivotal trials, which may be due to extensive follow-up treatments.

Published
2022

34. Current practice patterns of outpatient management of acute pulmonary embolism: A post-hoc analysis of the YEARS study

Author

Hendriks, S.V. (Stephan V.), Bavalia, R. (Roisin), Bemmel, T. (Thomas) van, Bistervels, I.M. (Ingrid M.), Eijsvogel, M., Faber, L.M. (L.), Fogteloo, J. (Jaap), Hofstee, H.M.A., van der Hulle, T. (Tom), Sol, A.I. (Antonio Iglesias), Kruip, M.J.H.A. (Marieke), Mairuhu, A.T.A., Middeldorp, S. (Saskia), Nijkeuter, M., Huisman, M.V. (Menno), Klok, F.A. (Frederikus), Hendriks, S.V. (Stephan V.), Bavalia, R. (Roisin), Bemmel, T. (Thomas) van, Bistervels, I.M. (Ingrid M.), Eijsvogel, M., Faber, L.M. (L.), Fogteloo, J. (Jaap), Hofstee, H.M.A., van der Hulle, T. (Tom), Sol, A.I. (Antonio Iglesias), Kruip, M.J.H.A. (Marieke), Mairuhu, A.T.A., Middeldorp, S. (Saskia), Nijkeuter, M., Huisman, M.V. (Menno), and Klok, F.A. (Frederikus)

Abstract

Background: Studies have shown the safety of home treatment of patients with pulmonary embolism (PE) at low risk of adverse events. Management studie

Published
2020
Full Text
View/download PDF

36. O009: Safety and efficiency of the YEARS diagnostic algorithm for pregnant patients with clinically suspected acute pulmonary embolism: the ARTEMIS study

Author

van der Pol, L.M., primary, Tromeur, C., additional, Bistervels, I.M., additional, NiAinle, F., additional, van Bemmel, T., additional, Buchmuller, A., additional, Couturaud, F., additional, van Dooren, Y.P.A., additional, Elias, A., additional, Faber, L.M., additional, Hofstee, H.M.A., additional, van der Hulle, T., additional, Kruip, M.J.H.A., additional, Maignan, M., additional, Mairuhu, A.T.A., additional, Middeldorp, S., additional, Nijkeuter, M., additional, Roy, P.M., additional, Sanchez, O., additional, Schmidt, J., additional, ten Wolde, M., additional, Klok, F.A., additional, and Huisman, M.V., additional

Published
2019
Full Text
View/download PDF

38. Clinical effects of antiplatelet drugs and statins on D-dimer levels

Author

Gelok, Suzanne, van der Hulle, T, Biedermann, Jossi, Gelder, Teun, Klok, FA, van der Pol, LM, Versmissen, Jorie, Huisman, MV, Kruip, Marieke, Gelok, Suzanne, van der Hulle, T, Biedermann, Jossi, Gelder, Teun, Klok, FA, van der Pol, LM, Versmissen, Jorie, Huisman, MV, and Kruip, Marieke

Published
2018

40. P1618Lower prevalence of isolated subsegmental pulmonary embolism in the YEARS diagnostic algorithm compared with the conventional algorithm for suspected pulmonary embolism

Author

Klok, F.A., primary, Van Der Pol, L.M., additional, Van Der Hulle, T., additional, Den Exter, P.L., additional, Van Werkhoven, J.M., additional, Van Mens, T.E., additional, Bistervels, I.M., additional, Mairuhu, A.T.A., additional, Ten Wolde, M., additional, Middeldorp, S., additional, and Huisman, M.V., additional

Published
2017
Full Text
View/download PDF

44. PO-07 - Excluding pulmonary embolism in cancer patients using the Wells rule and age-adjusted D-dimer testing: an individual patient data meta-analysis

Author

van Es, N., primary, van der Hulle, T., additional, van Es, J., additional, den Exter, P.L., additional, Douma, R.A., additional, Goekoop, R.J., additional, Mos, I.C.M., additional, Garcia, J.G., additional, Kamphuisen, P.W., additional, Huisman, M.V., additional, Klok, F.A., additional, Büller, H.R., additional, and Bossuyt, P.M., additional

Published
2016
Full Text
View/download PDF

47. Risk of Recurrent Venous Thromboembolism and Major Bleeding in Cancer-Associated Incidental Pulmonary Embolism Amongst Treated and Untreated Patients: A Pooled Analysis of 926 Patients

Author

van der Hulle, T, primary, den Exter, P L, additional, Meyer, G, additional, Planquette, B, additional, Soler, S, additional, Monreal, M, additional, Jimenez, D, additional, Portillo, A K, additional, O'Connell, C, additional, Liebman, H, additional, Shteinberg, M, additional, Adir, Y, additional, Tiseo, M, additional, Bersanelli, M, additional, Abdel-Razeq, H N, additional, Mansour, A H, additional, Donnelly, O G, additional, Radhakrishna, G, additional, Ramasamy, S, additional, Bozas, G, additional, Maraveyas, A, additional, Shinagare, A B, additional, Hatabu, H, additional, Nishino, M, additional, Huisman, M V, additional, and Klok, F A, additional

Published
2014
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results